Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2010 Mar 30;9(4):1019–1027. doi: 10.1158/1535-7163.MCT-09-0862

Figure 6.

Figure 6

Biodistribution of 0.25 nmol 18F-IMP-449 (5 MBq) 1 hour after injection, following pretargeting with 6.0 nmol TF2 16 hours earlier, biodistribution of 18F-IMP-449 without pretargeting, or biodistribution of Al[18F]2+ in BALB/c nude mice with a s.c. CEA-expressing LS174T tumor. Values are given as means ± standard deviation.